Applied Health Economics and Health Policy

, Volume 10, Issue 2, pp 87–97

Evaluating the epidemiology and morbidity burden associated with human papillomavirus in Israel

Accounting for CIN1 and genital warts in addition to CIN2/3 and cervical cancer
  • Oren Shavit
  • Raanan Raz
  • Michal Stein
  • Gabriel Chodick
  • Eduardo Schejter
  • Yehuda Ben-David
  • Raanan Cohen
  • Daphna Arbel
  • Varda Shalev
Original Research Article



Human papillomavirus (HPV) infection is mostly associated with cervical cancer (CC). However, it can cause other illnesses as well, all of which impact on people’s wellbeing and consume healthcare resources. Measures for prevention or early detection of these conditions differ in their effectiveness and cost. An informative evaluation of the projected benefit of these measures depends on understanding the current unmet need, not only limited to CC.


To evaluate the burden of HPV-related conditions in Israel, including CC, cervical precancerous lesions and genital warts.


A retrospective database analysis was conducted for the second largest health management organization (HMO) in Israel, covering approximately 1.8 million people. Records were drawn following a search for key words indicative of related diagnoses, lab results, medications, or procedures for the time period of 2006–2008. Prevalence, incidence and resource utilization were analysed. Findings were extrapolated to the whole Israeli population using age and gender incidence rates.


Incidence of CC was found to be 5 per 100000 females. Incidences of cervical intraepithelial neoplasia (CIN) grades 1, 2 and 3 were 74, 27 and 36 per 100 000 females, respectively. Incidence of genital warts was 239 and 185 per 100 000 for men and women, respectively. The overall annual economic burden was calculated to be $US48 838 058 (year 2010 values).


HPV poses a significant burden in terms of health (clinical and quality of life) and in monetary terms, even for conditions that are sometimes regarded as benign, such as CIN1 or genital warts. Current findings should be used for proper evaluation of measures to reduce HPV-related morbidity and mortality, such as regular screening and vaccination.


  1. 1.
    Garland SM, Smith JS. Human papillomavirus vaccines: current status and future prospects. Drugs 2010; 70(9): 1079–98PubMedCrossRefGoogle Scholar
  2. 2.
    de Villiers EM, Fauquet C, Broker TR, et al. Classification of papillomaviruses. Virology 2004; 324(1): 17–27PubMedCrossRefGoogle Scholar
  3. 3.
    Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006; 61(6 Suppl. 1): S3–14PubMedCrossRefGoogle Scholar
  4. 4.
    Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006; 24Suppl. 3: S3/11–25Google Scholar
  5. 5.
    Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24Suppl. 3: S3/35–41Google Scholar
  6. 6.
    Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004; 193(1): 35–44PubMedCrossRefGoogle Scholar
  7. 7.
    Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26Suppl. 10: K1–16PubMedCrossRefGoogle Scholar
  8. 8.
    Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007; 11(4): 223–39PubMedCrossRefGoogle Scholar
  9. 9.
    Wright Jr TC, Massad LS, Dunton CJ, et al. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J Low Genit Tract Dis 2007; 11(4): 201–22PubMedCrossRefGoogle Scholar
  10. 10.
    Mortensen GL, Larsen HK. The quality of life of patients with genital warts: a qualitative study. BMC Public Health 2010; 10: 113PubMedCrossRefGoogle Scholar
  11. 11.
    Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008; 84(3): 161–6PubMedCrossRefGoogle Scholar
  12. 12.
    Mortensen GL. Long-term quality of life effects of genital warts: a follow-up study. Dan Med Bull 2010; 57(4): A4140PubMedGoogle Scholar
  13. 13.
    Insinga RP, Glass AG, Myers ER, et al. Abnormal outcomes following cervical cancer screening: event duration and health utility loss. Med Decis Making 2007; 27(4): 414–22PubMedCrossRefGoogle Scholar
  14. 14.
    Annemans L, Remy V, Oyee J, et al. Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009; 27(3): 231–45PubMedCrossRefGoogle Scholar
  15. 15.
    Woodhall SC, Jit M, Cai C, et al. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009; 36(8): 515–21PubMedCrossRefGoogle Scholar
  16. 16.
    Szarewski A. HPV vaccine: Cervarix. Expert Opin Biol Ther 2010; 10(3): 477–87PubMedCrossRefGoogle Scholar
  17. 17.
    Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 2006; 66(9): 1263–71PubMedCrossRefGoogle Scholar
  18. 18.
    Ginsberg GM, Fisher M, Ben-Shahar I, et al. Cost-utility analysis of vaccination against HPV in Israel. Vaccine 2007; 25(37-38): 6677–91PubMedCrossRefGoogle Scholar
  19. 19.
    Israel National Cancer Registry. Cancer incidence tables — Cervix Uteri, 2007 [online]. Available from URL: [Accessed 2010 Sep 1]Google Scholar
  20. 20.
    Menczer J. The low incidence of cervical cancer in Jewish women: has the puzzle finally been solved? Isr Med Assoc J 2003; 5(2): 120–3PubMedGoogle Scholar
  21. 21.
    Sadan O, Schejter E, Ginath S, et al. Premalignant lesions of the uterine cervix in a large cohort of Israeli Jewish women. Arch Gynecol Obstet 2004; 269(3): 188–91PubMedCrossRefGoogle Scholar
  22. 22.
    Menczer J. The human papillomavirus vaccine and its relevance in Israel. Isr Med Assoc J 2007; 9(7): 546–9PubMedGoogle Scholar
  23. 23.
    Israel National Cancer Registry. Cancer in Israel: trends in incidence and mortality 1982-2002 and selected updated data, 2004 [online]. Available from URL: [Accessed 2010 Sep 1]Google Scholar
  24. 24.
    Israel Central Bureau of Statistics. Statistical abstract of Israel 2005 [online]. Available from URL: [Accessed 2010 Sep 1]Google Scholar
  25. 25.
    World Health Organisation. Cervical cancer, human papillomavirus (HPV), and HPV vaccines. Key points for policymakers and health professionals [online]. Available from URL: [Accessed 2010 Sep 1]
  26. 26.
    Arbyn M, Autier P, Ferlay J. Burden of cervical cancer in the 27 member states of the European Union: estimates for 2004. Ann Oncol 2007; 18(8): 1423–5PubMedCrossRefGoogle Scholar
  27. 27.
    Chodick G, Heymann AD, Wood F, et al. The direct medical cost of diabetes in Israel. Eur J Health Econ 2005; 6(2): 166–71PubMedCrossRefGoogle Scholar
  28. 28.
    Shalev V, Chodick G, Heymann AD. Format change of a laboratory test order form affects physician behavior. Int J Med Inform 2009; 78(10): 639–44PubMedCrossRefGoogle Scholar
  29. 29.
    Menczer J, Kogan L, Schejter E, et al. A population-based study of selected demographic characteristics of Israeli-Jewish women with cervical squamous cell carcinoma. Arch Gynecol Obstet 2011; 283(3): 629–33PubMedCrossRefGoogle Scholar
  30. 30.
    Israel Ministry of Health. Health Services tariff, 2010 [online]. Available from URL: [Accessed 2010 Jun 1]Google Scholar
  31. 31.
    Israel Ministry of Health. Israeli Health Insurance Law, 1994 [online]. Available from URL: [Accessed 2010 May 31]Google Scholar
  32. 32.
    National Insurance Institute of Israel. Sick Funds Membership, April 2010 [online]. Available from URL: [Accessed 2010 May 31]Google Scholar
  33. 33.
    Israel Central Bureau of Statistics. Statistical abstract of Israel, 2009 [online]. Available from URL: [Accessed 2010 Jun 1]Google Scholar
  34. 34.
    Israel Ministry of Health. Guidelines for the submission of a request to include a pharmaceutical product in the national list of health services, 2011 [online]. Available from URL: [Accessed 2011 Jul 1]Google Scholar
  35. 35.
    Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br Med J 2009; 339: b3884CrossRefGoogle Scholar
  36. 36.
    Israel Central Bureau of Statistics. National expenditure on Health, 2011 [online]. Available from URL: [Accessed 2011 Apr 1]Google Scholar
  37. 37.
    Henk HJ, Insinga RP, Singhal PK, et al. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis 2010; 14(1): 29–36PubMedCrossRefGoogle Scholar
  38. 38.
    Israel Ministry of Health. Israel national cancer registry, 2002 [online]. Available from URL: [Accessed 2008 Sep 1]Google Scholar
  39. 39.
    Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359(8): 821–32PubMedCrossRefGoogle Scholar
  40. 40.
    Center for the Evaluation of Value and Risk in Health. CEA Registry, 2010 [online]. Available from URL: 2010; [Accessed 2010 Aug 1]Google Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Oren Shavit
    • 1
    • 7
  • Raanan Raz
    • 2
  • Michal Stein
    • 3
  • Gabriel Chodick
    • 2
    • 4
  • Eduardo Schejter
    • 5
  • Yehuda Ben-David
    • 6
  • Raanan Cohen
    • 3
  • Daphna Arbel
    • 3
  • Varda Shalev
    • 2
    • 4
  1. 1.The School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael
  2. 2.Medical InformaticsMaccabi Healthcare ServicesTel AvivIsrael
  3. 3.MSD Israel Co. LtdHod-HasharonIsrael
  4. 4.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael
  5. 5.Tel-Aviv Women’s Health CenterMaccabi Healthcare ServicesTel AvivIsrael
  6. 6.Division of Gynecologic OncologyHaEmek Medical CenterAfulaIsrael
  7. 7.Division of Clinical Pharmacy, School of Pharmacy, Faculty of MedicineThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations